Viking Therapeutics Stock Surges on Acquisition Speculation
Published on 11/12/2025 at 19:52 | Redaktion boerse-global.de
Shares of Viking Therapeutics experienced significant upward momentum this week, fueled by renewed takeover speculation and a positive analyst update. The biotech firm’s stock climbed 7.49% to reach $40.60, extending its gains with an additional 4.1% advance in after-hours trading.
Market researchers at Canaccord Genuity reaffirmed their positive stance on Viking Therapeutics, maintaining a “Buy” recommendation while raising their price target. This move highlights the financial community’s continued confidence in the company’s developmental pipeline.
Viking has positioned itself as a key competitor in the rapidly expanding weight-loss medication sector through its GLP-1/GIP candidate VK2735. The growing focus on independent biotech companies follows Pfizer’s successful acquisition of Metsera, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
